StockpollyBeta
Get App
Popularity #2,913
SITC · NYSE · REIT - Retail

SITE Centers (SITC)

Selling remaining open-air shopping centers while monetizing DTP and Curbline ties.

$3.00
vs last close−0.06 (−1.96%)

  1. Bank of New York Mellon Corp Makes New $921,000 Investment in Site Centers Corp. $SITC

    Defense WorldOwnership

  2. Bessemer Group Inc. Raises Stock Position in Site Centers Corp. $SITC

    Defense World

  3. Caxton Associates LLP Sells 219,046 Shares of Site Centers Corp. $SITC

    Defense World

  4. Fisher Asset Management LLC Sells 182,310 Shares of Site Centers Corp. $SITC

    Defense World

  5. Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 14,531 Shares of Site Centers Corp. $SITC

    Defense World

  6. Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025

    PRNewsWire

  7. Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    GlobeNewsWire

  8. Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    GlobeNewsWire

  9. Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

    GlobeNewsWire

  10. MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

    GlobeNewsWire

  11. IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    GlobeNewsWire

  12. Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

    GlobeNewsWire

  13. Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

    GlobeNewsWire

  14. Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

    GlobeNewsWire

  15. BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

    GlobeNewsWire

  16. HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

    GlobeNewsWire

  17. Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

    GlobeNewsWire

  18. Candel Therapeutics to highlight immunotherapy advances at SITC 2025

    Proactive Investors

  19. Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

    GlobeNewsWire

  20. CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    GlobeNewsWire

  21. AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

    GlobeNewsWire

  22. Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

    GlobeNewsWire

  23. Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

    GlobeNewsWire

  24. Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

    GlobeNewsWire